Novartis has one of the industry's most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications. |
Kisqali ribociclib. CDK4 inhibitor. Hormone receptor-positive. Oncology. Oral. 2023. US, EU. (HR+)/human epidermal growth registration. |
Benefiting from our continued focus on innovation, Novartis has one of the industry's most innovative and inventive pipelines with ~150 projects in clinical ... |
Explore Our Pipeline. Novartis teams work to develop innovative pharmaceuticals that may help potentially advance standards of care worldwide. View the ... |
Benefiting from our continued focus on innovation, Novartis has one of the industry's most innovative and inventive pipelines with more than 160 projects in ... |
Our focus has allowed us to sharpen our commercial execution and increase our peak sales estimates for Cosentyx, Kisqali, Kesimpta, Pluvicto and ... |
Explore Our Pipeline. Novartis has one of the industry's most competitive pipelines. Information on investigational product(s) and/or investigational use(s) ... |
[PDF] Novartis Pipeline 2019 www.novartis.com › sites › files › novartis-pipeline-2019-annual-report
Adjuvant non-small cell lung cancer. Oncology. Subcutaneous injection 2017. 2022/III. AVXS-1011 onasemno- Survival motor neuron Spinal muscular atrophy. |
21 нояб. 2024 г. · Novartis slimmed down its clinical-stage programs by nearly 40% in recent years as the pharma “took to heart” data showing it wasn't getting ... |
| Novbeti > |
| Axtarisha Qayit Anarim.Az Anarim.Az Sayt Rehberliyi ile Elaqe Saytdan Istifade Qaydalari Anarim.Az 2004-2023 |